Intervacc AB — Investor Relations & Filings

Intervacc AB is a biotechnology company focused on developing a new generation of vaccines for animal health. The company's technology platform utilizes fusions of recombinant proteins, a modern approach that avoids attenuated live strains, based on research from the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead commercial product is Strangvac®, a vaccine for horses against strangles caused by Streptococcus equi. The development pipeline includes vaccine candidates targeting significant bacterial diseases, such as Streptococcus suis infections in pigs and Staphylococcus aureus-induced mastitis in dairy cows. Intervacc's mission is to improve animal health and welfare while contributing to the reduction of antibiotic use and combating antimicrobial resistance. The company manages sales and distribution through its subsidiary, Nordvacc.